HR 796 119th Congress House In Committee

Second Chance for Moms Act

Latest action: Referred to the House Committee on Energy and Commerce. · Jan 28, 2025

View full text on Congress.gov ↗ Policy area: Health

Legislative Summary

Second Chance for Moms Act of 2025 This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

Source: Congressional Research Service (CRS).

Sponsor

Rep. Miller, Mary E. [R-IL-15]
Independent · IL

Cosponsors (13)

Rep. Babin Rep. Moore Rep. Moore Rep. Ogles Rep. Webster Rep. Tenney Rep. Clyde Rep. Harris Rep. Weber Rep. Harris+3 more

Track HR 796 in BallotBox360

Get real-time bill updates, floor vote alerts, and AI-powered summaries — all in one app.

Download on iOS Open Web App